Supernus Announces Second Quarter 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015
August 11, 2014 5:10 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.08, may not compare to the analyst estimate of ($0.16). Revenue for the quarter came in at $29.67 million versus the consensus estimate of $19.85 million.
Financial Guidance
With the recognition of royalty revenues of $30 million in July, the Company is... More
